Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Regeneron Reports First Quarter 2018 Financial and Operating Results


      News provided by

      Regeneron Pharmaceuticals, Inc.

      May 03, 2018, 06:30 ET

      Share this article

      Share this article


      TARRYTOWN, N.Y., May 3, 2018 /PRNewswire/ --  

      • First quarter 2018 GAAP net income per diluted share increased by 93% to $4.16 versus first quarter 2017 and first quarter 2018 non-GAAP net income per diluted share increased 60% to $4.67 versus first quarter 2017
      • First quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 15% to $984 million versus first quarter 2017 and first quarter 2018 EYLEA global net sales(1) increased 20% to $1.61 billion versus first quarter 2017
      • Positive results reported from Praluent® (alirocumab) ODYSSEY OUTCOMES study
      • Agreement reached with Express Scripts that provides patients with straightforward and more affordable patient access to Praluent
      • Supplemental Biologics License Application for Dupixent® (dupilumab) in asthma accepted with a target action date of October 20, 2018
      • Biologics License Application for cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) accepted for priority review
      • Positive Phase 3 results reported for EYLEA in non-proliferative diabetic retinopathy trial

      Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2018 and provided a business update.

      "Regeneron's commercial business continues to advance with positive sales growth for EYLEA and strong underlying demand for Dupixent," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "This year, we have reported positive Phase 3 results for Praluent in cardiovascular risk reduction and for EYLEA in diabetic retinopathy - and look forward to continued progress with Dupixent, including a U.S. regulatory decision in uncontrolled asthma and Phase 3 results in both adolescents with atopic dermatitis and adults with nasal polyps.  Our immuno-oncology portfolio is advancing rapidly, with a potential first approval for cemiplimab in advanced cutaneous squamous cell carcinoma, and a broad pivotal program in lung cancer."

      Financial Highlights








      ($ in millions, except per share data)


      Three Months Ended
      March 31,



      2018


      2017


      % Change

      Total revenues


      $

      1,511



      $

      1,319



      15%

      GAAP net income


      $

      478



      $

      249



      92%

      GAAP net income per share - diluted


      $

      4.16



      $

      2.16



      93%

      Non-GAAP net income(2)


      $

      537



      $

      337



      59%

      Non-GAAP net income per share - diluted(2)


      $

      4.67



      $

      2.92



      60%













      Net Product Sales of Regeneron-Discovered Products*




      ($ in millions)


      Three Months Ended
      March 31,



      2018


      2017


      % Change

      EYLEA in the United States


      $

      984



      $

      854



      15%

      ARCALYST


      4



      4



      —%

      Net product sales recorded by Regeneron


      $

      988



      $

      858



      15%








      EYLEA outside of the United States*


      $

      624



      $

      484



      29%

      EYLEA global


      $

      1,608



      $

      1,338



      20%








      Global net product sales recorded by Sanofi*:





      Praluent in the United States


      $

      32



      $

      25



      28%

      Praluent outside of the United States


      28



      11



      155%

      Praluent global


      60



      36



      67%








      Dupixent in the United States


      117



      —



      **

      Dupixent outside of the United States


      14



      —



      **

      Dupixent global


      131



      —



      **








      Kevzara in the United States


      9



      —



      **

      Kevzara outside of the United States


      3



      —



      **

      Kevzara global


      12



      —



      **








      ZALTRAP global


      26



      17



      53%

      Net product sales recorded by Sanofi


      $

      229



      $

      53



      **








      * Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Praluent, Dupixent, Kevzara, and ZALTRAP.  Refer to Table 4 below for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and global sales of Praluent, Dupixent, and Kevzara.  Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP.

      ** Percentage not meaningful

      First Quarter 2018 Business Highlights

      Key Pipeline Progress

      Regeneron has seventeen product candidates in clinical development, which consist of EYLEA and fully human antibodies generated using the Company's VelocImmune® technology, including six in collaboration with Sanofi.  Updates from the clinical pipeline include:

      EYLEA® (aflibercept) Injection

      • In the first quarter of 2018, the Company announced positive top-line results from the Phase 3 PANORAMA study of EYLEA in moderately severe to severe non-proliferative diabetic retinopathy (NPDR).  PANORAMA will form the basis of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) by the end of the year.

      Dupixent® (dupilumab) Injection

      • Dupixent, an antibody that blocks signaling of IL-4 and IL-13, is currently approved in atopic dermatitis for adults in the United States, European Union, and certain other countries outside the United States.
      • Dupilumab is being studied in asthma, adolescent and pediatric atopic dermatitis, nasal polyps, and eosinophilic esophagitis (EoE), with additional studies planned in 2018. Data are expected to be reported from Phase 3 studies in patients with nasal polyps and adolescent patients with atopic dermatitis during 2018.
      • In March 2018, the sBLA for Dupixent as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma was filed with the FDA, with a target action date of October 20, 2018. In the first quarter of 2018, regulatory applications were also accepted for review by the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for Dupixent in asthma.
      • Dupixent for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in the first quarter of 2018, and has recently been launched.
      • In the first quarter of 2018, a Phase 2/3 study in younger pediatric patients (from six months to five years of age) with severe atopic dermatitis was initiated.

      Praluent® (alirocumab) Injection

      • In the first quarter of 2018, the Company and Sanofi announced that the ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone. In addition, in this study, adding Praluent to maximally-tolerated statins was associated with reduced death from any cause.
      • In May 2018, the Company and Sanofi announced they will lower the net price of Praluent in exchange for straightforward, more affordable patient access from Express Scripts. Praluent will become the exclusive PCSK9 inhibitor therapy on the Express Scripts national formulary. The agreement takes effect on July 1, 2018 for commercial patients covered by the Express Scripts National Preferred Formulary (approximately 25 million individuals in total).

      Cemiplimab, an antibody to programmed cell death protein 1 (PD-1), is being studied in patients with cancer.

      • In April 2018, the FDA accepted for priority review the BLA for cemiplimab for the treatment of patients with metastatic CSCC or patients with locally advanced CSCC who are not candidates for surgery. The target action date for the FDA decision is October 28, 2018.
      • In April 2018, the EMA also accepted for review the Marketing Authorization Application (MAA) for cemiplimab in patients with metastatic CSCC or patients with locally advanced CSCC who are not candidates for surgery.

      Fasinumab, an antibody targeting Nerve Growth Factor (NGF), is being studied in patients with osteoarthritis of the knee or hip and chronic low back pain in patients with concomitant osteoarthritis of the knee or hip.

      • An independent Data Monitoring Committee monitoring the ongoing safety and efficacy of the fasinumab clinical trials recommended that the higher dose-regimens be discontinued based on the risk benefit assessment and that the program may continue with the lower dose-regimens of fasinumab.  The trials are being modified accordingly.  

      Evinacumab is an antibody to angiopoietin-like protein 3 (ANGPTL3).  A Phase 3 study in homozygous familial hypercholesterolemia (HoFH) was initiated in the first quarter of 2018.

      REGN3500 is an antibody to interleukin-33 (IL-33).  In the first quarter of 2018, a Phase 2 study in asthma was initiated.

      Select Upcoming 2018 Milestones

      Programs


      Milestones

      EYLEA

      •

      FDA decision on sBLA for every 12-week dosing interval in wet AMD (target action date of August 11, 2018)


      •

      Submit sBLA for the treatment of NPDR in patients without DME


      •

      Submit sBLA for pre-filled syringe

      Dupixent (dupilumab)

      •

      FDA decision on sBLA for asthma in adult/adolescent patients (target action date of October 20, 2018)


      •

      Additional regulatory agency decisions on applications for atopic dermatitis in adults outside the United States


      •

      Report data from Phase 3 study in adolescent patients (12–17 years of age) with atopic dermatitis and submit sBLA and MAA for expanded indication


      •

      Report data from Phase 3 studies in nasal polyps


      •

      Initiate Phase 3 study in EoE


      •

      Initiate Phase 3 program in chronic obstructive pulmonary disease (COPD)


      •

      Initiate clinical program in co-morbid allergic conditions


      •

      Initiate Phase 2 studies in peanut allergy and grass allergy

      Praluent (alirocumab)

      •

      Submit for regulatory approval for cardiovascular risk reduction in the United States and EU and for first-line treatment of hyperlipidemia in the United States


      •

      FDA decision on sBLA for use with apheresis (target action date of August 24, 2018)


      •

      Initiate Phase 3 pediatric studies in HoFH and HeFH

      Kevzara (sarilumab)

      •

      Initiate Phase 3 study in giant cell arteritis


      •

      Initiate Phase 3 study in polymyalgia rheumatica

      Cemiplimab (PD-1 Antibody)

      •

      FDA decision on BLA for advanced CSCC (target action date of October 28, 2018)


      •

      Continue patient enrollment in Phase 3 study for first-line treatment of non-small cell lung cancer, as well as various other studies


      •

      Initiate additional studies in non-small cell lung cancer

      Fasinumab (NGF Antibody)

      •

      Report data from first Phase 3 efficacy study in osteoarthritis pain

      Evinacumab (Angptl-3 Antibody)

      •

      Initiate Phase 2 study in severe hypertriglyceridemia

      REGN3500 (IL-33 Antibody)

      •

      Initiate Phase 2 studies in COPD and atopic dermatitis

      Bispecific Antibodies

      •

      Initiate Phase 2 study for REGN1979 (CD20xCD3 Antibody) in Follicular Lymphoma


      •

      Initiate clinical study in REGN4018 (MUC16xCD3 antibody)


      •

      Submit Investigational New Drug Application (IND) for BCMAxCD3 antibody

      Financial Results

      Product Revenues: Net product sales were $988 million in the first quarter of 2018, compared to $858 million in the first quarter of 2017.  EYLEA net product sales in the United States were $984 million in the first quarter of 2018, compared to $854 million in the first quarter of 2017.  Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

      Total Revenues: Total revenues, which include product revenues described above, increased by 15% to $1.511 billion in the first quarter of 2018, compared to $1.319 billion in the first quarter of 2017.  Total revenues include Sanofi and Bayer collaboration revenues of $437 million in the first quarter of 2018, compared to $404 million in the first quarter of 2017.  Sanofi collaboration revenue in the first quarter of 2018 decreased primarily due to the Company's Discovery and Preclinical Development Agreement with Sanofi ending on December 31, 2017, lower reimbursement for Dupixent (dupilumab) development activities, and an increase in the Company's share of the collaborations' Dupixent commercialization expenses.  These decreases were partly offset by the Company's share of higher net sales of Dupixent (as the product was launched at the end of March 2017), and an increase in reimbursement revenues in connection with late-stage clinical development activities for cemiplimab.  Bayer collaboration revenue increased in the first quarter of 2018 primarily due to an increase in the Company's share of net profits in connection with higher sales of EYLEA outside the United States.

      Other revenue in the first quarter of 2018 increased primarily due to higher reimbursements of the Company's fasinumab research and development expenses in connection with the Company's collaboration agreement with Teva.

      The Company adopted Accounting Standard Codification (ASC) 606, Revenue from Contracts with Customers, as of January 1, 2018.  The Company adopted the standard using the modified retrospective method; prior period amounts have not been adjusted and the Company recognized a cumulative-effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143 million, net of tax.  The adoption of the new standard did not have a material impact of the Company's total revenues in the first quarter of 2018.  

      Refer to Table 4 for a summary of collaboration and other revenue.

      Research and Development (R&D) Expenses: GAAP R&D expenses were $499 million in the first quarter of 2018, compared to $507 million in the first quarter of 2017.  The lower R&D expenses in the first quarter of 2018 were principally due to a decrease in clinical manufacturing costs and a decrease in dupilumab development costs.  These decreases were partly offset by an increase in cemiplimab and fasinumab clinical trial costs.  In the first quarter of 2018, R&D-related non-cash share-based compensation expense was $41 million, compared to $74 million in the first quarter of 2017.  The decrease in total non-cash share-based compensation expense in the first quarter of 2018 was primarily attributable to a revision in the Company's estimate of the number of stock options that are expected to be forfeited.

      Selling, General, and Administrative (SG&A) Expenses: GAAP SG&A expenses were $331 million in the first quarter of 2018, compared to $297 million in the first quarter of 2017.  The higher SG&A expenses in the first quarter of 2018 were primarily due to higher headcount and headcount-related costs and an increase in commercialization-related expenses to support the launch of Dupixent.  In the first quarter of 2018, SG&A-related non-cash share-based compensation expense decreased to $35 million, compared to $54 million in the first quarter of 2017, primarily due to the revision in the Company's estimate of stock option forfeitures as described under "R&D Expenses" above.

      Income Tax Expense: In the first quarter of 2018, GAAP income tax expense was $107 million and the effective tax rate was 18.3%, compared to $183 million and 42.4% in the first quarter of 2017.  The Company's effective tax rate for the first quarter of 2018 was significantly impacted by the bill known as the Tax Cuts and Jobs Act (the "U.S. Tax Reform Act"), which reduced the U.S. federal corporate income tax rate from 35% to 21% effective January 1, 2018.  The effective tax rate for the first quarter of 2018 was positively impacted, compared to the U.S. federal statutory rate, primarily by the foreign-derived intangible income deduction and the federal tax credit for research activities.

      Other income, net: GAAP other income in the first quarter of 2018 included the recognition of unrealized gains on equity securities.  In the first quarter of 2018, the Company adopted Accounting Standards Update ("ASU") 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, as of January 1, 2018, which requires the Company to measure equity investments at fair value with changes in fair value recognized in net income; previously, such changes in fair value were recognized in Other comprehensive income (loss).  Refer to Table 3 for the non-GAAP adjustment related to these gains.

      GAAP and Non-GAAP Net Income(2): GAAP net income was $478 million, or $4.44 per basic share and $4.16 per diluted share, in the first quarter of 2018, compared to GAAP net income of $249 million, or $2.36 per basic share and $2.16 per diluted share, in the first quarter of 2017.

      Non-GAAP net income was $537 million, or $4.99 per basic share and $4.67 per diluted share, in the first quarter of 2018, compared to non-GAAP net income of $337 million, or $3.19 per basic share and $2.92 per diluted share, in the first quarter of 2017.

      A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

      2018 Financial Guidance(3)

      The Company's updated full year 2018 financial guidance consists of the following components:

      Sanofi collaboration revenue: Sanofi      
      reimbursement of Regeneron
      commercialization-related expenses     

      $450 million–$485 million

      (previously $450 million–$500 million)

      Non-GAAP unreimbursed R&D(2)(4)

      $1.230 billion–$1.310 billion

      (previously $1.230 billion–$1.330 billion)

      Non-GAAP SG&A(2)(4)

      $1.325 billion–$1.395 billion

      (previously $1.350 billion–$1.450 billion)

      Effective tax rate

      15%–18%

      (previously 15%–19%)

      Capital expenditures

      $420 million–$480 million

      (previously $420 million–$500 million)



      (1)

      Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer collaboration revenue" in its Statements of Operations.



      (2)

      This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, and non-GAAP SG&A, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  These non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure.  Non-GAAP adjustments also include the estimated income tax effect of reconciling items.

      The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance.  For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's equity investments) or items that are not associated with normal, recurring operations (such as changes in applicable laws and regulations).  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.



      (3)

      The Company's 2018 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.



      (4)

      A reconciliation of full year 2018 non-GAAP to GAAP financial guidance is included below:








      Projected Range




      (In millions)


      Low


      High




      GAAP unreimbursed R&D (5)


      $

      1,445



      $

      1,545





      R&D: Non-cash share-based compensation expense


      (215)



      (235)





      Non-GAAP unreimbursed R&D


      $

      1,230



      $

      1,310













      GAAP SG&A


      $

      1,490



      $

      1,590





      SG&A: Non-cash share-based compensation expense


      (165)



      (195)





      Non-GAAP SG&A


      $

      1,325



      $

      1,395




      (5)

      Unreimbursed R&D represents R&D expenses reduced by R&D expense reimbursements from the Company's collaborators and/or customers.





      Conference Call Information

      Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2018 financial and operating results on Thursday, May 3, 2018, at 8:30 AM.  To access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International).  A link to the webcast may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

      About Regeneron Pharmaceuticals, Inc.

      Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in Regeneron's laboratories.  Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases, and rare diseases.

      Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

      For additional information about the Company, please visit www.regeneron.com or follow @Regeneron on Twitter.

      Forward-Looking Statements and Use of Digital Media

      This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation EYLEA® (aflibercept) Injection, Dupixent® (dupilumab) Injection, Praluent® (alirocumab) Injection, Kevzara® (sarilumab) Injection, cemiplimab, fasinumab, and evinacumab; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA, Dupixent, Praluent, and Kevzara), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to Sanofi reimbursement of Regeneron commercialization-related expenses, non-GAAP unreimbursed R&D, non-GAAP SG&A, effective tax rate, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to Praluent, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

      Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

      Non-GAAP Financial Measures

      This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

      Contact Information:






      Manisha Narasimhan, Ph.D.


      Hala Mirza

      Investor Relations


      Corporate Communications

      914-847-5126


      914-847-3422

      [email protected]


      [email protected]

      TABLE 1

      REGENERON PHARMACEUTICALS, INC.

      CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

      (In thousands)




      March 31,


      December 31,



      2018


      2017

      Assets:





      Cash and marketable securities


      $

      3,446,937



      $

      2,896,074


      Accounts receivable - trade, net


      1,531,936



      1,538,642


      Accounts receivable from Sanofi and Bayer


      411,996



      435,698


      Inventories


      820,397



      726,138


      Property, plant, and equipment, net


      2,394,727



      2,358,605


      Deferred tax assets


      532,268



      506,291


      Other assets


      234,435



      302,838


        Total assets


      $

      9,372,696



      $

      8,764,286







      Liabilities and stockholders' equity:





      Accounts payable, accrued expenses, and other liabilities


      $

      1,043,749



      $

      967,418


      Deferred revenue


      1,056,658



      949,337


      Capital and facility lease obligations


      704,645



      703,453


      Stockholders' equity


      6,567,644



      6,144,078


        Total liabilities and stockholders' equity


      $

      9,372,696



      $

      8,764,286


      TABLE 2

      REGENERON PHARMACEUTICALS, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

      (In thousands, except per share data)




      Three Months Ended
      March 31,



      2018


      2017

      Revenues:





      Net product sales


      $

      987,909



      $

      858,245


      Sanofi collaboration revenue


      189,490



      210,367


      Bayer collaboration revenue


      247,928



      193,939


      Other revenue


      86,158



      56,440





      1,511,485




      1,318,991


      Expenses:





      Research and development


      498,586



      507,435


      Selling, general, and administrative


      330,770



      296,846


      Cost of goods sold


      69,243



      61,253


      Cost of collaboration and contract manufacturing


      45,655



      22,915




      944,254



      888,449







      Income from operations


      567,231



      430,542







      Other income, net


      18,167



      1,747







      Income before income taxes


      585,398



      432,289







      Income tax expense


      (107,418)



      (183,358)







      Net income


      $

      477,980



      $

      248,931







      Net income per share - basic


      $

      4.44



      $

      2.36


      Net income per share - diluted


      $

      4.16



      $

      2.16







      Weighted average shares outstanding - basic


      107,648



      105,572


      Weighted average shares outstanding - diluted


      114,906



      115,106


      TABLE 3

      REGENERON PHARMACEUTICALS, INC.

      RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME (Unaudited)

      (In thousands, except per share data)




      Three Months Ended
      March 31,



      2018


      2017

      GAAP net income


      $

      477,980



      $

      248,931


      Adjustments:





      R&D: Non-cash share-based compensation expense


      40,835



      73,523


      SG&A: Non-cash share-based compensation expense


      35,014



      53,812


      COGS and COCM: Non-cash share-based compensation expense


      6,573



      6,454


      Other income/expense: Gains and losses on investments in equity securities (a)


      (9,369)



      —


      Income tax effect of reconciling items above


      (14,301)



      (46,179)


        Non-GAAP net income


      $

      536,732



      $

      336,541







      Non-GAAP net income per share - basic


      $

      4.99



      $

      3.19


      Non-GAAP net income per share - diluted


      $

      4.67



      $

      2.92







      Shares used in calculating:





      Non-GAAP net income per share - basic


      107,648



      105,572


      Non-GAAP net income per share - diluted


      114,910



      115,178







      (a) Prior to the quarter ended March 31, 2018, unrealized gains and losses on equity securities were recorded in Other comprehensive income (loss).  In connection with the adoption of ASU 2016-01, unrealized gains and losses on equity securities during the three months ended March 31, 2018 were recorded in Other income, net.

      TABLE 4

      REGENERON PHARMACEUTICALS, INC.

      COLLABORATION AND OTHER REVENUE (Unaudited)

      (In thousands)




      Three Months Ended
      March 31,



      2018


      2017

      Sanofi collaboration revenue:





      Reimbursement of Regeneron research and development expenses


      $

      134,218



      $

      213,924


      Reimbursement of Regeneron commercialization-related expenses


      86,634



      73,559


      Regeneron's share of losses in connection with commercialization of antibodies


      (74,874)



      (108,402)


      Other


      43,512



      31,286


        Total Sanofi collaboration revenue


      189,490



      210,367







      Bayer collaboration revenue:





      Regeneron's net profit in connection with commercialization of EYLEA outside the
         United States


      232,068



      174,876


      Reimbursement of Regeneron development expenses


      3,997



      6,349


      Other


      11,863



      12,714


        Total Bayer collaboration revenue


      247,928



      193,939







      Total Sanofi and Bayer collaboration revenue


      $

      437,418



      $

      404,306







      Other revenue:





      Reimbursement of Regeneron research and development expenses - Teva


      $

      39,129



      $

      22,050


      Reimbursement of Regeneron research and development expenses - other


      2,695



      2,650


      Other


      44,334



      31,740


        Total other revenue


      $

      86,158



      $

      56,440


      SOURCE Regeneron Pharmaceuticals, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.